What is the management of Fetal Growth Restriction (FGR)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Fetal Growth Restriction (FGR)

The management of fetal growth restriction requires a structured approach based on umbilical artery Doppler findings, with specific timing of delivery determined by the severity of growth restriction and Doppler abnormalities. 1

Diagnosis and Classification

FGR is defined as:

  • Estimated fetal weight (EFW) or abdominal circumference (AC) below the 10th percentile for gestational age 1
  • Severe FGR: EFW below the 3rd percentile 1

Classification by timing:

  • Early-onset FGR: Diagnosed <32 weeks gestation
  • Late-onset FGR: Diagnosed ≥32 weeks gestation 1, 2

Initial Evaluation

  1. Detailed ultrasound examination

    • Recommended for early-onset FGR (<32 weeks) as up to 20% of cases are associated with fetal or chromosomal abnormalities 1
  2. Genetic testing

    • Offer prenatal diagnostic testing with chromosomal microarray analysis (CMA) when:
      • FGR is detected with fetal malformation and/or polyhydramnios (any gestational age) 1
      • Unexplained isolated FGR diagnosed at <32 weeks 1
  3. Infectious disease evaluation

    • Not recommended to screen for toxoplasmosis, rubella, or herpes without other risk factors
    • PCR for cytomegalovirus recommended in women with unexplained FGR who undergo amniocentesis 1

Monitoring Protocol

Umbilical Artery Doppler Surveillance

For EFW between 3rd-10th percentile:

  • Initial Doppler assessment every 1-2 weeks for 1-2 weeks
  • If stable, can decrease to every 2-4 weeks 1
  • Weekly cardiotocography (CTG) testing after viability 1
  • Consider EFW assessment every 2 weeks; at minimum every 3-4 weeks 1

For EFW <3rd percentile (severe FGR):

  • Weekly umbilical artery Doppler evaluation 1
  • Weekly CTG testing 1
  • Consider EFW assessment every 2 weeks 1

For abnormal umbilical artery Doppler findings:

  • Decreased end-diastolic velocity: Weekly Doppler evaluation 1
  • Absent end-diastolic velocity (AEDV): Doppler assessment 2-3 times per week 1
  • Reversed end-diastolic velocity (REDV): Hospitalization, daily CTG (at least 1-2 times/day), antenatal corticosteroids, and consideration of delivery 1

Other Doppler Studies

  • Ductus venosus, middle cerebral artery, or uterine artery Doppler are not recommended for routine clinical management of early or late-onset FGR 1
  • These may provide additional information in specialized centers but should not guide routine care 1

Timing of Delivery

Timing is based on umbilical artery Doppler findings and severity of growth restriction:

  1. Normal umbilical artery Doppler with EFW between 3rd-10th percentile:

    • Deliver at 38-39 weeks gestation 1
  2. Decreased diastolic flow (without AEDV/REDV) or severe FGR (EFW <3rd percentile):

    • Deliver at 37 weeks gestation 1
  3. Absent end-diastolic velocity (AEDV):

    • Deliver at 33-34 weeks gestation 1
  4. Reversed end-diastolic velocity (REDV):

    • Deliver at 30-32 weeks gestation 1

Delivery Considerations

  1. Mode of delivery

    • Systematic cesarean deliveries for FGR are not universally recommended 3
    • For pregnancies with FGR complicated by AEDV/REDV, cesarean delivery should be considered based on the clinical scenario 1
  2. Antenatal corticosteroids

    • Recommended if delivery is anticipated before 33 6/7 weeks 1
    • Also recommended for pregnancies between 34 0/7 and 36 6/7 weeks in women at risk of preterm delivery within 7 days 1
  3. Magnesium sulfate

    • Recommended for fetal and neonatal neuroprotection for pregnancies <32 weeks gestation 1

Maternal Monitoring

  • Monitor closely for development of hypertensive disorders, as maternal hypertension is common in early-onset FGR (present in 50% during pregnancy and 70% at delivery) 4
  • Maternal hypertension is associated with earlier delivery, lower birthweights, and poorer outcomes 4

Pitfalls and Caveats

  1. Avoid unnecessary activity restriction

    • Activity restriction is not recommended for in utero treatment of FGR 1
  2. Avoid ineffective treatments

    • Low-molecular-weight heparin and sildenafil are not recommended for prevention or treatment of FGR 1, 4
  3. Recognize the importance of gestational age

    • The single most important prognostic factor in preterm fetuses with growth restriction is gestational age at delivery 4
    • There is a 1-2% increase in intact survival for every additional day spent in utero up until 32 weeks 4
  4. Standardized protocols improve outcomes

    • Following a standardized protocol for diagnosis and management is associated with more favorable outcomes 4
  5. Consider long-term implications

    • Children born with FGR have higher risks of minor cognitive deficits, school problems, and metabolic syndrome in adulthood 3

By following this structured approach to FGR management, focusing on appropriate monitoring intervals and evidence-based timing of delivery based on Doppler findings, clinicians can optimize outcomes for these high-risk pregnancies.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fetal growth restriction: current knowledge.

Archives of gynecology and obstetrics, 2017

Guideline

Fetal Growth Restriction Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.